Alto Neuroscience, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Amelioration of Neural Deficits Associated with Diabetes (US 10,322,115) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Amelioration of Certain Deficiencies Due to Stroke (US 10,413,534) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 2 fees due May 14, 2027
- 1 fee due Sep 8, 2027The maintenance fee for Synthesis of a Neurostimulative Piperazine (US 9,278,933) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 17 US 12,797,373 Combination Therapy for a Dopamine Agonist
- 1 term has ended since Aug 23, 2026
- Oct 8 US 8,293,488 Method for Screening Neurogenic Agents · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,673,916 | Methods of Treating Disorders Mediated by Histamine H3 Receptors Using Pyridazinone Derivatives In force · High confidence | In force | High confidence | |
| US 8,207,168 | Pyridazinone Derivatives In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 8,586,588 | Aryl Pyridazinone Derivatives and Their Use as H3 Receptor Ligands In force · High confidence | In force | High confidence | |
| US 8,247,414 | Pyridizinone Derivatives and the Use Thereof as H3 Inhibitors In force · High confidence | In force | High confidence | |
| US 8,524,713 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands In force · High confidence | In force | High confidence | |
| US 9,278,933 | Synthesis of a Neurostimulative Piperazine In force · High confidence | In force | High confidence | |
| US 9,481,649 | Synthesis of a neurostimulative piperazine In force · USPTO record | In force | USPTO record | |
| US 9,572,807 | Protocols for Treatment of Major Depressive Disorder (MDD) In force · High confidence | In force | High confidence | |
| US 10,322,115 | Amelioration of Neural Deficits Associated with Diabetes In force · High confidence | In force | High confidence | |
| US 10,413,534 | Amelioration of Certain Deficiencies Due to Stroke In force · High confidence | In force | High confidence |
Also on record, not counted in the 21: 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 9 abandoned